These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38292170)

  • 1. Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network.
    Li S; Zou T; Chen J; Li J; You J
    Genes Dis; 2024 May; 11(3):101064. PubMed ID: 38292170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
    Su X; Kong Y; Peng D
    Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease.
    Ye DW; Rong XL; Xu AM; Guo J
    Chin J Integr Med; 2017 Jun; 23(6):410-414. PubMed ID: 28795382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
    Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
    Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.
    BonDurant LD; Potthoff MJ
    Annu Rev Nutr; 2018 Aug; 38():173-196. PubMed ID: 29727594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential function and clinical application of FGF21 in metabolic diseases.
    Chen Z; Yang L; Liu Y; Huang P; Song H; Zheng P
    Front Pharmacol; 2022; 13():1089214. PubMed ID: 36618930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
    Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
    Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.
    Woo YC; Xu A; Wang Y; Lam KS
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):489-96. PubMed ID: 23134073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases.
    Yan J; Nie Y; Cao J; Luo M; Yan M; Chen Z; He B
    Front Cardiovasc Med; 2021; 8():655575. PubMed ID: 33869312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21.
    Gong Q; Zhang X; Sun Y; Shen J; Li X; Xue C; Liu Z
    J Mol Med (Berl); 2022 Nov; 100(11):1587-1597. PubMed ID: 36102936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development.
    Liu J; Dalamaga M
    Metabol Open; 2021 Dec; 12():100153. PubMed ID: 34917917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.
    Li Y; Wong K; Giles A; Jiang J; Lee JW; Adams AC; Kharitonenkov A; Yang Q; Gao B; Guarente L; Zang M
    Gastroenterology; 2014 Feb; 146(2):539-49.e7. PubMed ID: 24184811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD.
    Wang Z; Sun T; Yu J; Li S; Gong L; Zhang Y
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):351. PubMed ID: 38179757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of FGF21 and its analogs on liver associated diseases.
    Falamarzi K; Malekpour M; Tafti MF; Azarpira N; Behboodi M; Zarei M
    Front Med (Lausanne); 2022; 9():967375. PubMed ID: 36457562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF21 in obesity and cancer: New insights.
    Lu W; Li X; Luo Y
    Cancer Lett; 2021 Feb; 499():5-13. PubMed ID: 33264641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic receptors are critical for weight loss but not for other metabolic adaptations to the consumption of a ketogenic diet in male mice.
    Douris N; Desai BN; Fisher FM; Cisu T; Fowler AJ; Zarebidaki E; Nguyen NLT; Morgan DA; Bartness TJ; Rahmouni K; Flier JS; Maratos-Flier E
    Mol Metab; 2017 Aug; 6(8):854-862. PubMed ID: 28752049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 21 and bone homeostasis.
    Tang Y; Zhang M
    Biomed J; 2023 Aug; 46(4):100548. PubMed ID: 35850479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice.
    Liu XH; Graham ZA; Harlow L; Pan J; Azulai D; Bauman WA; Yarrow J; Cardozo CP
    Front Endocrinol (Lausanne); 2021; 12():668984. PubMed ID: 34046014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.
    Zhang F; Yu L; Lin X; Cheng P; He L; Li X; Lu X; Tan Y; Yang H; Cai L; Zhang C
    Mol Endocrinol; 2015 Oct; 29(10):1400-13. PubMed ID: 26308386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.